Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer.
Sarat Chandarlapaty, MD, PhD
Advertisement
Sarat Chandarlapaty, MD, PhD, is an associate attending medical oncologist and a laboratory head in the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.
Articles by Sarat Chandarlapaty, MD, PhD
Dr Chandarlapaty discusses the AMEERA-1 trial and its impact on the ER+/HER2- metastatic breast cancer landscape.
An expert introduces amcenestrant as a potential new therapy for ER+/HER2- metastatic breast cancer and addresses how it differs from current treatment options.
Dr Chandarlapaty elaborates on the challenges and unmet needs seen when treating ER+/HER2- metastatic breast cancer.
A medical oncologist discusses the available treatment options for ER+/HER2- metastatic breast cancer.
Sarat Chandarlapaty, MD, gives an overview of ER+/HER2- metastatic breast cancer, including characteristics, diagnosis, and prognosis.
Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.
Advertisement
Latest Updated Articles
Emerging Therapies in ER+ Metastatic Breast CancerPublished: July 26th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
